Extended Migraine Prophylactics Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Extended Migraine Prophylactics Market 

5.1. COVID-19 Landscape: Extended Migraine Prophylactics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Extended Migraine Prophylactics Market, By Product Type

8.1. Extended Migraine Prophylactics Market Revenue and Volume, by Product Type

8.1.1. Oral Tablets & Capsules

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Injectables/Biologics

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Nasal Sprays

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Transdermal Patches

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Oral Liquids/Solutions

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Extended Migraine Prophylactics Market, By Mechanism of Action

9.1. Extended Migraine Prophylactics Market Revenue and Volume, by Mechanism of Action

9.1.1. Calcitonin Gene-Related Peptide (CGRP) Inhibitors

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Beta-blockers

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Antiepileptics/Neuromodulators

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Tricyclic Antidepressants (TCAs)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Serotonin Antagonists/SSRIs

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global Extended Migraine Prophylactics Market, By Route of Administration 

10.1. Extended Migraine Prophylactics Market Revenue and Volume, by Route of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Injectable

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Nasal

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Transdermal

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Other Routes

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Extended Migraine Prophylactics Market, By Treatment Type

11.1. Extended Migraine Prophylactics Market Revenue and Volume, by Treatment Type

11.1.1. Preventive/Prophylactic Therapy

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Acute/Rescue Therapy

11.1.2.1. Market Revenue and Volume Forecast

Chapter 12. Global Extended Migraine Prophylactics Market, By Distribution Channel

12.1. Extended Migraine Prophylactics Market Revenue and Volume, by Distribution Channel

12.1.1. Retail Pharmacies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Hospital Pharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Online Pharmacies/E-commerce

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Specialty Clinics/Neurology Centers

12.1.4.1. Market Revenue and Volume Forecast

12.1.5. Others

12.1.5.1. Market Revenue and Volume Forecast

Chapter 13. Global Extended Migraine Prophylactics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Product Type

13.1.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.4. Market Revenue and Volume Forecast, by Treatment Type

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Product Type

13.1.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.4. Market Revenue and Volume Forecast, by Treatment Type

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Product Type

13.1.7.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.7.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.4. Market Revenue and Volume Forecast, by Treatment Type

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Product Type

13.2.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.4. Market Revenue and Volume Forecast, by Treatment Type  

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Product Type

13.2.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.7. Market Revenue and Volume Forecast, by Treatment Type  

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Product Type

13.2.9.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.9.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.10. Market Revenue and Volume Forecast, by Treatment Type

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Product Type

13.2.12.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.12.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.4. Market Revenue and Volume Forecast, by Treatment Type

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Product Type

13.2.14.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.14.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.4. Market Revenue and Volume Forecast, by Treatment Type

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Product Type

13.3.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.4. Market Revenue and Volume Forecast, by Treatment Type

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Product Type

13.3.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.4. Market Revenue and Volume Forecast, by Treatment Type

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Product Type

13.3.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.4. Market Revenue and Volume Forecast, by Treatment Type

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Product Type

13.3.10.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.4. Market Revenue and Volume Forecast, by Treatment Type

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Product Type

13.3.11.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.4. Market Revenue and Volume Forecast, by Treatment Type

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Product Type

13.4.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.4. Market Revenue and Volume Forecast, by Treatment Type

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Product Type

13.4.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.4. Market Revenue and Volume Forecast, by Treatment Type

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Product Type

13.4.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.4. Market Revenue and Volume Forecast, by Treatment Type

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Product Type

13.4.10.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.4. Market Revenue and Volume Forecast, by Treatment Type

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Product Type

13.4.11.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.4. Market Revenue and Volume Forecast, by Treatment Type

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Product Type

13.5.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.4. Market Revenue and Volume Forecast, by Treatment Type

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Product Type

13.5.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.4. Market Revenue and Volume Forecast, by Treatment Type

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Product Type

13.5.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.4. Market Revenue and Volume Forecast, by Treatment Type

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Eli Lilly

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Novartis

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Teva Pharmaceuticals

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Novo Nordisk

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Pfizer

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Johnson & Johnson

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. UCB

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Merck & Co

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Allergan

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Biohaven Pharmaceuticals

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms